MARKET

RGNX

RGNX

Regenxbio
NASDAQ
13.01
+0.03
+0.23%
Opening 14:24 12/05 EST
OPEN
13.06
PREV CLOSE
12.98
HIGH
13.29
LOW
12.87
VOLUME
253.80K
TURNOVER
--
52 WEEK HIGH
13.93
52 WEEK LOW
5.04
MARKET CAP
658.61M
P/E (TTM)
-3.7573
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RGNX last week (1124-1128)?
Weekly Report · 4d ago
Regenxbio files $300M mixed shelf offering
Seeking Alpha · 11/26 22:34
Regenxbio files $300M mixed securities shelf
TipRanks · 11/26 21:20
REGENXBIO INC FILES FOR MIXED SHELF OF UP TO $300 MLN - SEC FILING
Reuters · 11/26 21:16
Regenxbio Inc. to Join Piper Sandler Healthcare Conference
Reuters · 11/25 12:05
REGENXBIO to Participate in Upcoming Investor Conference
PR Newswire · 11/25 12:05
Weekly Report: what happened at RGNX last week (1117-1121)?
Weekly Report · 11/24 09:41
REGENXBIO Is Maintained at Buy by Chardan Capital
Dow Jones · 11/20 12:41
More
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Webull offers Regenxbio Inc stock information, including NASDAQ: RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.